StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI)

StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report released on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Down 9.1 %

Shares of NASDAQ:BCLI opened at $0.60 on Wednesday. The company has a market capitalization of $29.40 million, a price-to-earnings ratio of -1.36 and a beta of 0.22. Brainstorm Cell Therapeutics has a 52 week low of $0.13 and a 52 week high of $3.46. The firm has a 50 day moving average of $0.37 and a 200 day moving average of $0.34.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

A number of large investors have recently made changes to their positions in BCLI. Tower Research Capital LLC TRC increased its position in shares of Brainstorm Cell Therapeutics by 739.2% during the first quarter. Tower Research Capital LLC TRC now owns 8,862 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 7,806 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Brainstorm Cell Therapeutics during the second quarter worth $33,000. XTX Topco Ltd acquired a new position in shares of Brainstorm Cell Therapeutics during the first quarter worth $40,000. GTS Securities LLC acquired a new position in shares of Brainstorm Cell Therapeutics during the third quarter worth $41,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Brainstorm Cell Therapeutics during the second quarter worth $47,000. 14.33% of the stock is owned by institutional investors and hedge funds.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.